Latest News

Dr Reddy’s receives EIR for Bachupally unit from USFDA

Dr Reddy’s Laboratories has received an establishment inspection report (EIR) for Bachupally unit, Hyderabad, after the closure of its audit from the US Food and Drug Administration.

The audit for this formulation manufacturing plant 3 was conducted in April, by the USFDA and it issued a form 483 with 11 observations.

Further, this clearance from USFDA means that the company has resolved all the observations which were stated by the US health regulator.

Read EquityPandit’s Technical Analysis on Dr Reddy

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



📰
News
📈
Prediction
📊
FII / DII
👔
Advisory
Get 1-2 Index Option Trades Daily